India Drug Regulator Takes New Step In Adding To Approval Procedure
This article was originally published in PharmAsia News
Executive SummaryThe Drug Controller General of India has selected six laboratories it intends to rely on to test drugs before they are allowed on the Indian market. The DCGI said it is considering the system for making the review process work, including a public-private partnership arrangement. The agency is considering adding the testing procedure instead of relying solely on clinical trial data submitted by drug makers as an additional guarantee of quality. The six government labs have been identified as capable of providing the testing envisioned. (Click here for more
You may also be interested in...
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.
Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.
Nearly 500 shipments of illegal and unapproved prescription drugs and combination medical devices were seized at US borders thanks to Operation Broadsword.